WESTHX extract: "two cancer therapies approved in recent years have shown clear (overall)survival benefits—Dendreon’s Provenge vaccine and BMS’ Yervoy (ipilimumab) antibody for melanoma: “For Provenge, you have no PFS improvement at all. For ipilimumab, there is a PFS improvement, but it is smaller than the survival improvement. So in both cases, I would say, it’s very clear that (overall)survival(OS) is the right endpoint.”
I have reposted this extract here to emphasize the significance of OS (rather than PFS) in the 2 products -Provenge(Dendreon) and Yervoy (Bristol-Myers Squibb) which have received FDA approval as an immunotherapy treatment.
cheers
Birdseye
WESTHX extract: "two cancer therapies approved in recent years...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |